News

Both have issued further statements regarding the deal.

The procedure showed positive effects on the electroretinography (ERG) (b-wave, oscillatory potentials), optomotor response, and contrast sensitivity in actively treated eyes compared with controls.

A stepwise guide to optimize astigmatism management in cataract surgery

A pair of studies, conducted in Taiwan and China, indicate that red light therapy could serve as an effective and safe alternative to atropine

From early experiences in India to fellowship training at Wills Eye Hospital, Dr. Ansari discusses how ophthalmologists can make a lasting impact worldwide.

Biomarkers and fine-tuned staging are key to progress in improving retinal care, according to Fanka Gilevska, MD, PhD

Learn how the YOURS Committee empowers young retina specialists through engaging educational initiatives, networking opportunities, and exam preparation resources.

Oculis plans to commence its PIONEER program, consisting of 3 trials, by the end of the year.

Catch up on this week's highlights in retina.

Discover key insights from leading ophthalmology experts at the AAO meeting, featuring presentations, posters, and innovative discussions from October 17-20.

NPI-001 is Nacuity’s investigational therapy for the treatment of patients with retinitis pigmentosa (RP).

Additionally, the company also received Clinical Trial Authorisation (CTA) approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).

Holz discusses advancements in retinal disease treatments at the EURETINA meeting, featuring gene therapy and innovative implants to enhance patient care.

A study reveals diverse ocular symptoms in Sjögren’s disease, linking eye features to oral and pain manifestations for personalized treatment strategies.

A recent study reveals that most UK patients with geographic atrophy find intravitreal complement inhibitors acceptable, emphasizing the importance of perceived visual benefits.

The Eye Care Network spoke with Sebastian Wolf, MD, PhD, and Sophie Bonnin, MD, PhD, who presented new findings from the OCS-05 phase 2 ACUITY trial.

Vizz is the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults

As of October 1, 2025, the Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code (J3403) to revakinagene taroretcel-lwey.

Behind the scenes of building impactful educational platforms in retina care

Lupin notes that the acquisition will help to strengthen the company by “integrating VISUfarma’s established commercial operations.”